Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01772693 · ClinicalTrials.gov registry record · NA
ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease
A NA study, sponsored by InSightec.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT01772693 is a NA study that has completed, run by InSightec. The registered enrollment target is 27 participants.
The verdict
NCT01772693, a NA study, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a feasibility study to evaluate the safety and initial effectiveness of unilateral ExAblate thermal ablation of the Vim thalamic nucleus of subjects suffering from medication-refractory, idiopathic, tremor-dominant PD, using the ExAblate Transcranial system compared to a Sham Vim thalamotomy procedure. Data will be collected to establish the basic safety of this type of treatment as the basis for later studies that will evaluate its full clinical efficacy. The Sham treatment data will be used to evaluate placebo effect from treatment.
Interventions
- DEVICE ExAblate Transcranial MRgFUS
- DEVICE Sham ExAblate Transcranial MRgFUS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-09 |
| Est. Completion | 2019-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01772693
The ClinicalTrials.gov registry entry for NCT01772693 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ExAblate Transcranial MRgFUS is the first listed.
NCT01772693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01772693 about?
NCT01772693 is a clinical study titled "ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease". This is a feasibility study to evaluate the safety and initial effectiveness of unilateral ExAblate thermal ablation of the Vim thalamic nucleus of subjects suffering from medication-refractory, idiopathic, tremor-dominant PD, using the ExAblate Transcranial system compared to a Sham Vim thalamotomy...
What is the current status of trial NCT01772693?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2012-09. Estimated completion is 2019-03.
What interventions are being tested in trial NCT01772693?
The interventions under investigation include: ExAblate Transcranial MRgFUS (DEVICE), Sham ExAblate Transcranial MRgFUS (DEVICE).
Who is sponsoring clinical trial NCT01772693?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.